The Effect of the NorGeP-NH on Quality of Life and Drug Prescriptions in Norwegian Nursing Homes: A Randomized Controlled Trial.
nursing homes
psychotropic polypharmacy
structured drug review
Journal
Pharmacy (Basel, Switzerland)
ISSN: 2226-4787
Titre abrégé: Pharmacy (Basel)
Pays: Switzerland
ID NLM: 101678532
Informations de publication
Date de publication:
16 Feb 2022
16 Feb 2022
Historique:
received:
10
01
2022
revised:
31
01
2022
accepted:
09
02
2022
entrez:
24
2
2022
pubmed:
25
2
2022
medline:
25
2
2022
Statut:
epublish
Résumé
The effect of the Norwegian General Practice-Nursing Home (NorGeP-NH) criteria has never been tested on clinical outcomes in nursing home (NH) residents. We performed a cluster-randomized trial in Norwegian NHs and tested the effect of NorGeP-NH on QoL (primary outcome), medication prescriptions, and physical and mental health (secondary outcomes) for the enrolled residents; Methods: Fourteen NHs were randomized into intervention NHs (iNHs) and control NHs (cNHs). After baseline data collection, physicians performed NorGeP-NH on the enrolled residents. We assessed the difference between cNHs and iNHs in the change in primary outcome from baseline to 12 weeks and secondary outcomes from baseline to eight and 12 weeks by linear mixed models; Results: One hundred and eight residents (13 lost to follow-up) and 109 residents (nine lost to follow-up) were randomized to iNHs and cNHs, respectively. Difference in change in QoL at 12 weeks between cNHs and iNHs was not statistically significant (mean (95% CI)): -1.51 (-3.30; 0.28), Our intervention did not affect QoL or drug prescriptions, but reduced depression scores in the iNHs. NorGeP-NH may be a useful tool, but its effect on clinical outcomes may be scarce in NH residents. Further studies about the effectiveness of NorGeP-NH in other healthcare contexts and settings are recommended.
Sections du résumé
BACKGROUND
BACKGROUND
The effect of the Norwegian General Practice-Nursing Home (NorGeP-NH) criteria has never been tested on clinical outcomes in nursing home (NH) residents. We performed a cluster-randomized trial in Norwegian NHs and tested the effect of NorGeP-NH on QoL (primary outcome), medication prescriptions, and physical and mental health (secondary outcomes) for the enrolled residents; Methods: Fourteen NHs were randomized into intervention NHs (iNHs) and control NHs (cNHs). After baseline data collection, physicians performed NorGeP-NH on the enrolled residents. We assessed the difference between cNHs and iNHs in the change in primary outcome from baseline to 12 weeks and secondary outcomes from baseline to eight and 12 weeks by linear mixed models; Results: One hundred and eight residents (13 lost to follow-up) and 109 residents (nine lost to follow-up) were randomized to iNHs and cNHs, respectively. Difference in change in QoL at 12 weeks between cNHs and iNHs was not statistically significant (mean (95% CI)): -1.51 (-3.30; 0.28),
CONCLUSIONS
CONCLUSIONS
Our intervention did not affect QoL or drug prescriptions, but reduced depression scores in the iNHs. NorGeP-NH may be a useful tool, but its effect on clinical outcomes may be scarce in NH residents. Further studies about the effectiveness of NorGeP-NH in other healthcare contexts and settings are recommended.
Identifiants
pubmed: 35202081
pii: pharmacy10010032
doi: 10.3390/pharmacy10010032
pmc: PMC8880047
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Norwegian Health Association
ID : 2019/FO246675
Organisme : Dam Foundation
ID : 2019/FO246675
Organisme : Lions Clubs International Norway - Skjeberg
ID : AB3415
Références
Consult Pharm. 2017 Apr 1;32(4):228-238
pubmed: 28376988
J Am Med Dir Assoc. 2000 May-Jun;1(3):114-6
pubmed: 12818023
Eur Geriatr Med. 2021 Jun;12(3):443-452
pubmed: 33694123
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
BMJ. 2014 Mar 07;348:g1687
pubmed: 24609605
Int Psychogeriatr. 2012 Jan;24(1):62-73
pubmed: 21682940
Dement Geriatr Cogn Disord. 2015;40(3-4):233-42
pubmed: 26227299
Int Psychogeriatr. 2007 Feb;19(1):103-14
pubmed: 16805925
Cochrane Database Syst Rev. 2018 Sep 03;9:CD008165
pubmed: 30175841
Eval Health Prof. 2021 Jun;44(2):180-185
pubmed: 31964170
Int Psychogeriatr. 2021 Oct;33(10):1083-1098
pubmed: 33407955
JAMA Netw Open. 2018 Oct 5;1(6):e183750
pubmed: 30646263
J Am Geriatr Soc. 1999 Apr;47(4):487-91
pubmed: 10203127
Int Psychogeriatr. 2021 Jun;33(6):577-586
pubmed: 32431251
Eur Geriatr Med. 2021 Jun;12(3):463-473
pubmed: 33738772
J Am Geriatr Soc. 1991 Feb;39(2):142-8
pubmed: 1991946
Biol Psychiatry. 1988 Feb 1;23(3):271-84
pubmed: 3337862
Br J Clin Pharmacol. 2014 Jan;77(1):201-10
pubmed: 23711082
Arch Intern Med. 1991 Sep;151(9):1825-32
pubmed: 1888249
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
Dtsch Arztebl Int. 2010 Aug;107(31-32):543-51
pubmed: 20827352
Age Ageing. 2015 Mar;44(2):213-8
pubmed: 25324330
Aging Ment Health. 2015 Jan;19(1):13-31
pubmed: 24881888
J Am Med Dir Assoc. 2019 Mar;20(3):330-339
pubmed: 30630722
Drugs Aging. 2009;26(6):493-503
pubmed: 19591524
Health Qual Life Outcomes. 2011 Nov 03;9:95
pubmed: 22054205
Br J Psychiatry. 1979 Apr;134:382-9
pubmed: 444788
Scand J Prim Health Care. 2009;27(3):153-9
pubmed: 19462339
Eur Geriatr Med. 2020 Oct;11(5):863-868
pubmed: 32462509
Int Psychogeriatr. 2008 Apr;20(2):375-82
pubmed: 17559707
JAMA. 2018 Jun 12;319(22):2289-2298
pubmed: 29896627
BMJ. 2012 Sep 04;345:e5661
pubmed: 22951546
BMC Health Serv Res. 2017 May 22;17(1):365
pubmed: 28532443
Neurology. 1994 Dec;44(12):2308-14
pubmed: 7991117
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
BMC Geriatr. 2020 Sep 9;20(1):336
pubmed: 32907532
J Am Geriatr Soc. 2015 Dec;63(12):e1-e7
pubmed: 26446776
J Gen Intern Med. 1999 Jan;14(1):27-34
pubmed: 9893088
Eur J Clin Pharmacol. 2019 May;75(5):627-637
pubmed: 30662995
BMC Med Inform Decis Mak. 2019 May 29;19(1):102
pubmed: 31142298
Eur J Clin Pharmacol. 2015 Jul;71(7):861-75
pubmed: 25967540
Drugs Aging. 2018 Jan;35(1):43-60
pubmed: 29350335
Dement Geriatr Cogn Disord. 2021;50(2):103-110
pubmed: 34167127
Scand J Prim Health Care. 2015 Jun;33(2):134-41
pubmed: 26100966
Arch Intern Med. 2003 Dec 8-22;163(22):2716-24
pubmed: 14662625
Eur J Clin Pharmacol. 2018 Jun;74(6):679-700
pubmed: 29589066
Br J Clin Pharmacol. 2017 May;83(5):942-952
pubmed: 27891666
Cochrane Database Syst Rev. 2016 Feb 12;2:CD009095
pubmed: 26866421
Eur J Clin Pharmacol. 2019 Apr;75(4):467-481
pubmed: 30610274
J Am Med Dir Assoc. 2016 Sep 1;17(9):821-7
pubmed: 27321869
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
Int J Geriatr Psychiatry. 2004 Jan;19(1):19-26
pubmed: 14716695
Pharmacy (Basel). 2019 Mar 05;7(1):
pubmed: 30841495
Dtsch Arztebl Int. 2021 Oct 22;118(42):705-712
pubmed: 34366004
BMJ Open. 2016 Mar 16;6(3):e010278
pubmed: 26983947